Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
PURPOSE: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical manageme...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296182/ https://www.ncbi.nlm.nih.gov/pubmed/35802838 http://dx.doi.org/10.1200/GO.22.00030 |
_version_ | 1784750215008354304 |
---|---|
author | Behel, Vichitra Noronha, Vanita Choughule, Anuradha Shetty, Omshree Chandrani, Pratik Kapoor, Akhil Bondili, Suresh Kumar Bajpai, Jyoti Kumar, Rajiv Pai, Trupti Bal, Munita Gurav, Mamta Bapat, Prachi Mittal, Neha Menon, Santosh Patil, Vijay Menon, Nandini Dutt, Amit Prabhash, Kumar |
author_facet | Behel, Vichitra Noronha, Vanita Choughule, Anuradha Shetty, Omshree Chandrani, Pratik Kapoor, Akhil Bondili, Suresh Kumar Bajpai, Jyoti Kumar, Rajiv Pai, Trupti Bal, Munita Gurav, Mamta Bapat, Prachi Mittal, Neha Menon, Santosh Patil, Vijay Menon, Nandini Dutt, Amit Prabhash, Kumar |
author_sort | Behel, Vichitra |
collection | PubMed |
description | PURPOSE: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical management of patients with cancer. METHODS: This study was conducted at a tertiary cancer center in India. Cases to be discussed in the MTB were identified by molecular pathologists, scientists, or oncologists. On the basis of the clinical data and molecular test reports, a course of clinical management was recommended and made available to the treating oncologist. We determined the proportion of patients who were recommended a change in the clinical management. We also assessed compliance of the treating oncologists with MTB recommendations. RESULTS: There were 339 discussions for 328 unique patients. The median age of the cohort was 54 years (range 17-87), and the majority of the patients were men (65.1%). Of 339 cases, 133 (39.2%) were recommended continuation of ongoing therapy while the remaining 206 (60.7%) were recommended a change in clinical management. Compliance with MTB recommendations for a change in clinical management was 58.5% (79 of 138 evaluable cases). Compliance and implementation for MTB's recommendation to start a new therapy in 104 evaluable cases were 60.5% and 44.2%, respectively. A total of 248 biopsies had at least one actionable mutation. A total of 646 mutations were identified in the cohort, with EGFR being the most frequently altered gene. CONCLUSION: MTBs help in interpreting results of molecular tests, understanding the significance of molecular abnormalities, and assessing the benefits of available targeted therapies and clinical trials in the management of patients with targetable genetic alterations. |
format | Online Article Text |
id | pubmed-9296182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-92961822022-08-01 Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer Behel, Vichitra Noronha, Vanita Choughule, Anuradha Shetty, Omshree Chandrani, Pratik Kapoor, Akhil Bondili, Suresh Kumar Bajpai, Jyoti Kumar, Rajiv Pai, Trupti Bal, Munita Gurav, Mamta Bapat, Prachi Mittal, Neha Menon, Santosh Patil, Vijay Menon, Nandini Dutt, Amit Prabhash, Kumar JCO Glob Oncol ORIGINAL REPORTS PURPOSE: Multidisciplinary molecular tumor boards (MTBs) help in interpreting complex genomic data generated by molecular tumor profiling and improve patients' access to targeted therapies. The purpose of this study was to assess the impact of our institution's MTB on the clinical management of patients with cancer. METHODS: This study was conducted at a tertiary cancer center in India. Cases to be discussed in the MTB were identified by molecular pathologists, scientists, or oncologists. On the basis of the clinical data and molecular test reports, a course of clinical management was recommended and made available to the treating oncologist. We determined the proportion of patients who were recommended a change in the clinical management. We also assessed compliance of the treating oncologists with MTB recommendations. RESULTS: There were 339 discussions for 328 unique patients. The median age of the cohort was 54 years (range 17-87), and the majority of the patients were men (65.1%). Of 339 cases, 133 (39.2%) were recommended continuation of ongoing therapy while the remaining 206 (60.7%) were recommended a change in clinical management. Compliance with MTB recommendations for a change in clinical management was 58.5% (79 of 138 evaluable cases). Compliance and implementation for MTB's recommendation to start a new therapy in 104 evaluable cases were 60.5% and 44.2%, respectively. A total of 248 biopsies had at least one actionable mutation. A total of 646 mutations were identified in the cohort, with EGFR being the most frequently altered gene. CONCLUSION: MTBs help in interpreting results of molecular tests, understanding the significance of molecular abnormalities, and assessing the benefits of available targeted therapies and clinical trials in the management of patients with targetable genetic alterations. Wolters Kluwer Health 2022-07-08 /pmc/articles/PMC9296182/ /pubmed/35802838 http://dx.doi.org/10.1200/GO.22.00030 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Behel, Vichitra Noronha, Vanita Choughule, Anuradha Shetty, Omshree Chandrani, Pratik Kapoor, Akhil Bondili, Suresh Kumar Bajpai, Jyoti Kumar, Rajiv Pai, Trupti Bal, Munita Gurav, Mamta Bapat, Prachi Mittal, Neha Menon, Santosh Patil, Vijay Menon, Nandini Dutt, Amit Prabhash, Kumar Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer |
title | Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer |
title_full | Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer |
title_fullStr | Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer |
title_full_unstemmed | Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer |
title_short | Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer |
title_sort | impact of molecular tumor board on the clinical management of patients with cancer |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296182/ https://www.ncbi.nlm.nih.gov/pubmed/35802838 http://dx.doi.org/10.1200/GO.22.00030 |
work_keys_str_mv | AT behelvichitra impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT noronhavanita impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT choughuleanuradha impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT shettyomshree impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT chandranipratik impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT kapoorakhil impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT bondilisureshkumar impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT bajpaijyoti impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT kumarrajiv impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT paitrupti impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT balmunita impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT guravmamta impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT bapatprachi impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT mittalneha impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT menonsantosh impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT patilvijay impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT menonnandini impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT duttamit impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer AT prabhashkumar impactofmoleculartumorboardontheclinicalmanagementofpatientswithcancer |